Kyverna Therapeutics falls on $100 mln stock sale plans

Kyverna Therapeutics

15/12/2025 21:38

** Kyverna Therapeutics' KYTX.O shares down 6.9% in extended trading to $10.08 following planned equity raise news

    ** Emeryville, California-based KYTX announces proposed $100 mln stock offering

** KYTX stock surged 23.2% to close at $10.82 on Mon after co said its experimental cell therapy, miv-cel, for treatment of a rare movement disorder met the main goal in a mid-stage study

** Co has ~43.8 mln shares outstanding for roughly $475 mln market cap

** J.P. Morgan, Leerink, Morgan Stanley and Wells Fargo are joint book-running managers for the offering

    ** Through Mon, shares have nearly tripled YTD

    ** All 6 analysts are bullish including 2 "strong buy" ratings; median PT of $29 up from $22.50 on Nov 15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))